Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Local delivery of lipid-based nanoparticles containing microbial nucleic acid for osteoimmunomodulation.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025

Same author

Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity.

International journal of pharmaceutics·2024

Same author

Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration.

Journal of controlled release : official journal of the Controlled Release Society·2024

Same author

Osteoimmunomodulatory GelMA/liposome coatings to promote bone regeneration of orthopedic implants.

Journal of controlled release : official journal of the Controlled Release Society·2023

Same author

A robust post-insertion method for the preparation of targeted siRNA LNPs.

International journal of pharmaceutics·2022

Same author

Influence of short term storage conditions, concentration methodsand excipients on extracellular vesicle recovery and function.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2021

Search research articles

Related Experiment Video

Updated: May 26, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Polymeric carrier systems for siRNA delivery.

P Vader¹, L J van der Aa, G Storm

¹Division of Pharmaceutics, Utrecht Inistitute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands. p.vader@uu.nl

Current Topics in Medicinal Chemistry

|December 27, 2011

Summary

Polymeric carriers improve short interfering RNA (siRNA) delivery for gene silencing. Advances focus on optimizing intracellular trafficking, stabilization, and targeting, while addressing safety for clinical use.

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Assembly and Characterization of Polyelectrolyte Complex Micelles

Assembly and Characterization of Polyelectrolyte Complex Micelles

Published on: March 2, 2020

Related Experiment Videos

Last Updated: May 26, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Assembly and Characterization of Polyelectrolyte Complex Micelles

Assembly and Characterization of Polyelectrolyte Complex Micelles

Published on: March 2, 2020

Area of Science:

Biotechnology
Nanomedicine
Molecular Biology

Background:

RNA interference (RNAi) enables sequence-specific gene silencing.
Inefficient delivery of short interfering RNA (siRNA) hinders RNAi therapeutic applications.
Polymeric carrier systems offer a promising solution for siRNA delivery.

Purpose of the Study:

To review recent advancements in siRNA delivery using polymeric carriers.
To discuss strategies for enhancing siRNA intracellular trafficking and stability.
To explore in vivo targeting methods and clinical safety considerations for nanocarriers.

Main Methods:

Review of literature on polymeric nanoparticles for siRNA delivery.
Analysis of structural modifications of polymers for improved cellular uptake.
Examination of targeting ligands and stabilization techniques for in vivo applications.

Main Results:

Polymeric carriers demonstrate significant potential for enhancing siRNA delivery efficiency.
Structural variations in polymers can optimize intracellular trafficking and endosomal escape.
Targeting strategies and in vivo stabilization are crucial for therapeutic efficacy.
Emerging safety concerns necessitate careful nanocarrier design for clinical translation.

Conclusions:

Polymeric systems represent a key strategy for overcoming siRNA delivery barriers.
Further research into optimized nanocarrier design is essential for safe and effective RNAi therapeutics.
Balancing efficacy with safety is paramount for the clinical application of siRNA delivery systems.